Reviewed August 28, 2026
Is BPC-157 Legal? FDA Status and Licensed Care Options
A committee recommendation is not FDA approval. Here is exactly what changed, and what did not.
The short answer
- FDA status
- Not an FDA-approved drug product
- July 2026 vote
- Advisory committee recommended for the 503A bulks list process
- Reviewed for
- Ulcerative colitis
- Current federal 503A list
- Not named in 21 CFR 216.23 as of August 28, 2026
The committee recommended this compound continue in FDA's 503A bulks-list process. That non-binding recommendation was not drug approval, did not itself change federal law, and did not establish safety or effectiveness. The current federal list in 21 CFR 216.23 does not name this compound.
Why “is it legal” has no yes-or-no answer
For peptides, access is not a single switch. It depends on the FDA status of the substance, whether a compounding pathway applies, what your state’s pharmacy and medical boards permit, and whether a licensed clinician has evaluated you and written a prescription. Any source giving you a flat yes or no is skipping at least three of those.
BPC-157 is the peptide most likely to be misrepresented after the July 2026 vote, because it is the one with the loudest consumer marketing behind it. It has circulated for years in the fitness and recovery world with claims about tendons, joints, and gut repair. None of that is what the advisory committee examined.
What the advisory committee actually reviewed
The committee's review centered on ulcerative colitis - a specific inflammatory bowel condition with a defined clinical population. That is a narrow, serious medical context. It is not a general recovery or wellness endorsement, and a clinic that presents it as one is telling you something the regulatory record does not support.
Recovery, injury, gut, and anti-aging marketing is not what the committee reviewed.
What a committee recommendation is — and is not
The Pharmacy Compounding Advisory Committee advises the FDA. Its recommendations can shape what the agency does next, but the FDA is not required to follow them, and a recommendation is not a drug approval, a safety finding, a prescription, or proof that any clinic can offer something today. The FDA meeting record and the current 21 CFR 216.23 text are the authoritative sources.
Questions people ask
Did the FDA approve BPC-157 in July 2026?
No. An advisory committee recommended it continue in the 503A bulks list process. The committee advises the FDA; it does not approve drugs, and the FDA is not required to follow the recommendation.
Does the recommendation mean I can buy BPC-157 now?
No. A recommendation about compounding eligibility is not permission to purchase. Any legitimate path runs through a licensed clinician and a licensed pharmacy.
Why does my clinic say BPC-157 is for injury recovery?
Recovery marketing is not the context the committee reviewed. Ask the clinic which human study supports that specific use, and which licensed pharmacy would be involved.
Does the vote say BPC-157 is safe or that it works?
No. A regulatory recommendation about compounding eligibility is not a safety finding and not evidence of effectiveness for any condition.
Finding licensed care
If you want to talk to someone who can actually evaluate your situation, start with a licensed clinic. We list clinics by city and publish what we verified about each one, with the date we verified it.
Clinics we list: Phoenix, AZ, Scottsdale, AZ, Beverly Hills, CA, Los Angeles, CA